000130470 001__ 130470
000130470 005__ 20240125162930.0
000130470 0247_ $$2doi$$a10.23736/S0375-9393.20.14589-9
000130470 0248_ $$2sideral$$a123344
000130470 037__ $$aART-2021-123344
000130470 041__ $$aeng
000130470 100__ $$aSerrano, A.B.
000130470 245__ $$aNeuromuscular blockade management and postoperative outcomes in enhanced recovery colorectal surgery: secondary analysis of POWER trial
000130470 260__ $$c2021
000130470 5203_ $$aBACKGROUND: We evaluated the impact of neuromuscular blockade (NMB) management, monitoring and reversal on postoperative outcomes in colorectal surgical patients included in an enhanced recovery program.
METHODS: We performed a predefined analysis in 2084 patients undergoing elective colorectal surgery who participated in POWER study. We analyzed them for complications, length of hospital stay and mortality. Two groups were defined: 1) monitoring + reversal of the neuromuscular blockade (M+R) group: all patients receiving neuromuscular blockade monitoring plus reversal of it with any drug (neostigmine or sugammadex) were included; and 2) no monitoring nor reversal (noM+noR) group. In this group all the patients who did not receive monitoring and reversal of the neuromuscular blockade were allocated.
RESULTS: Multivariate analysis found no statistically significant differences in moderate-severe complications (174 [25.7%] vs. 124 [27.1%]; P=0.607), length of hospital stay (10.8±11.1 vs. 11.0 ±12.6 days; P=0.683) and mortality (6 [0.9%] vs. 5 [1.1%]; P=0.840) between the group receiving optimal neuromuscular management (M+R) and the one did not receive it (noM+noR). Univariate analysis showed patients reversed with neostigmine died more than those reversed with sugammadex (3 [2.7%] vs. 3 [0.5%]; P=0.048).
CONCLUSIONS: Our data suggest optimal neuromuscular blockade management in colorectal surgery is not associated with less moderate-severe complications, length of hospital stay or death during postoperative period in an enhanced recovery program. Neostigmine reversal seems to be linked to higher rate of mortality than sugammadex.
000130470 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000130470 590__ $$a3.396$$b2021
000130470 591__ $$aCRITICAL CARE MEDICINE$$b20 / 35 = 0.571$$c2021$$dQ3$$eT2
000130470 591__ $$aANESTHESIOLOGY$$b18 / 34 = 0.529$$c2021$$dQ3$$eT2
000130470 592__ $$a0.539$$b2021
000130470 593__ $$aAnesthesiology and Pain Medicine$$c2021$$dQ2
000130470 594__ $$a4.2$$b2021
000130470 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000130470 700__ $$aDíaz-Cambronero, O.
000130470 700__ $$aMelchor-Ripollés, J.
000130470 700__ $$aAbad-Gurumeta, A.
000130470 700__ $$0(orcid)0000-0001-7964-1166$$aRamírez-Rodríguez, J.M.$$uUniversidad de Zaragoza
000130470 700__ $$0(orcid)0000-0003-2462-1904$$aMartínez-Ubieto, J.$$uUniversidad de Zaragoza
000130470 700__ $$aSánchez-Merchante, M.
000130470 700__ $$aRodríguez, R.
000130470 700__ $$aJordá, L.
000130470 700__ $$aGil-Trujillo, S.
000130470 700__ $$aCabellos-Olivares, M.
000130470 700__ $$0(orcid)0000-0001-9444-606X$$aBordonaba-Bosque, D.$$uUniversidad de Zaragoza
000130470 700__ $$aAldecoa, C.
000130470 7102_ $$11013$$2090$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Cirugía
000130470 7102_ $$14014$$2623$$aUniversidad de Zaragoza$$bDpto. Economía Aplicada$$cÁrea Métodos Cuant.Econ.Empres
000130470 773__ $$g87, 1 (2021), 13-25$$pMinerva anestesiol.$$tMinerva Anestesiologica$$x0375-9393
000130470 8564_ $$s487744$$uhttps://zaguan.unizar.es/record/130470/files/texto_completo.pdf$$yVersión publicada
000130470 8564_ $$s2624348$$uhttps://zaguan.unizar.es/record/130470/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000130470 909CO $$ooai:zaguan.unizar.es:130470$$particulos$$pdriver
000130470 951__ $$a2024-01-25-15:13:23
000130470 980__ $$aARTICLE